Secondary Logo

Journal Logo

Heggelund Lars; Mollnes, Tom Eirik; Ueland, Thor; Christophersen, Bjørn; Aukrust, Pål; Frøland, Stig S.
JAIDS Journal of Acquired Immune Deficiency Syndromes: April 1st, 2003
BASIC SCIENCE: PDF Only
Free

To gain insight into the possible role of mannose-binding lectin (MBL) in HIV infection, we analyzed serum levels and the functional complement activation capacity of MBL in different clinical stages of HIV infection during cross-sectional analysis (n = 62) and longitudinal testing (n = 23) as well as during highly active antiretroviral therapy (HAART) (n = 40). The results were correlated with serum levels of C-reactive protein (CRP). Our main findings were as follows. MBL levels and the capacity of complement activation by the MBL pathway were increased in HIV-infected patients with advanced clinical disease as shown in both cross-sectional analysis and longitudinal testing. There was no “normalization” of these parameters during HAART. In fact, MBL levels increased during therapy, and this increase was associated with a good virologic response. Although both MBL and CRP are regarded as acute-phase proteins, no correlation was seen between these proteins. Thus, the notably diverse patterns of MBL responses among patients with different clinical courses and treatments suggest that MBL and complement activation by the MBL pathway could be involved in the pathophysiology of HIV infection. It is not inconceivable that the net effects of MBL responses may vary in different clinical settings.

This work was supported by the Research Council of Norway, the Norwegian Cancer Society, the Medinnova Foundation, and Odd Kåre Rabben's Memorial Fund for AIDS Research.

Address correspondence and reprint requests to Lars Heggelund. Section of Clinical Immunology and Infectious Diseases and Research Institute for Internal Medicine, Medical Department, Rikshospitalet. N-0027, Oslo, Norway; e-mail: lars.heggelund@klinmed.uio.no

Manuscript received October 15, 2002; accepted December 13, 2002.

© 2003 Lippincott Williams & Wilkins, Inc.